Back

Type I IFN-activated lung monocytes and macrophages as initiators and drivers of fibrosis at the alveolar barrier in IPF

Nathwani, V.; Weeratunga, P.; Woo, J.; Denney, L.; Vuppusetty, C.; Hu, T.; Zulfikar, S.; Achaiah, A.; Parker, H.; Chuang, H.-w.; Mazurczyk, M.; Fedorov, A.; Simmons, A.; Clelland, C.; Rehwinkel, J.; Antanaviciute, A.; Ho, L.-p.

2025-05-11 respiratory medicine
10.1101/2025.05.09.25326523 medRxiv
Show abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited therapeutic options. Although macrophages have been implicated in pathogenesis in murine models, their role in human disease remains unclear. Here, we present a comprehensive, unbiased single-cell transcriptomic and regulon atlas of myeloid cells from the alveolar barrier and lung tissue. We demonstrate that alveolar barrier macrophages are transcriptionally distinct from their lung tissue counterparts, exhibiting a striking upregulation of type I interferon (IFN) signalling in IPF. Circulating monocytes from IPF patients are primed for type I IFN responses, particularly in early disease, and monocytes are enriched with type I IFN-associated genes at lung sites of early fibrosis. These findings suggest a central role for type I IFN-activated monocytes in the initiation of fibrosis, and for alveolar barrier-related, type I IFN-activated macrophages in perpetuating fibrosis. These insights provide a rationale for therapeutically targeting monocytes in early stages of IPF.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.